Kythera Biopharmaceuticals Company Profile (NASDAQ:KYTH)

About Kythera Biopharmaceuticals (NASDAQ:KYTH)

Kythera Biopharmaceuticals logoKYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:KYTH
  • CUSIP: 50157010
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $74.78
  • 200 Day Moving Avg: $62.97
  • 52 Week Range: $29.86 - $76.31
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.72
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -12,900.69%
  • Return on Equity: -93.97%
  • Return on Assets: -72.56%
Misc:
  • Average Volume: 636,730 shs.
 

Frequently Asked Questions for Kythera Biopharmaceuticals (NASDAQ:KYTH)

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

How were Kythera Biopharmaceuticals' earnings last quarter?

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) issued its earnings results on Thursday, August, 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.34. The firm had revenue of $288 million for the quarter. Kythera Biopharmaceuticals had a negative return on equity of 93.97% and a negative net margin of 12,900.69%. View Kythera Biopharmaceuticals' Earnings History.

Who are some of Kythera Biopharmaceuticals' key competitors?

How do I buy Kythera Biopharmaceuticals stock?

Shares of Kythera Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kythera Biopharmaceuticals' stock price today?

One share of Kythera Biopharmaceuticals stock can currently be purchased for approximately $74.98.


MarketBeat Community Rating for Kythera Biopharmaceuticals (NASDAQ KYTH)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  71
MarketBeat's community ratings are surveys of what our community members think about Kythera Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kythera Biopharmaceuticals (NASDAQ:KYTH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Earnings by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Earnings History by Quarter for Kythera Biopharmaceuticals (NASDAQ KYTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q2($1.10)($1.44)$288.00 millionViewN/AView Earnings Details
3/2/2015Q414($1.07)($1.07)ViewN/AView Earnings Details
8/7/2014Q2($0.83)($0.86)ViewListenView Earnings Details
5/8/2014Q1($0.67)($0.76)ViewListenView Earnings Details
3/17/2014Q413($0.69)($0.66)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.70)($0.67)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.97)($0.77)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.76)($1.04)ViewN/AView Earnings Details
11/13/2012Q312($11.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Current Year EPS Consensus Estimate: $-4.45 EPS
Next Year EPS Consensus Estimate: $-3.30 EPS

Dividends

Dividend History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Insider Trades by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Institutional Ownership by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Insider Trades by Quarter for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Frederick Beddingfield IIIinsiderSell110,638$74.91$8,287,892.58View SEC Filing  
9/24/2015John W. SmitherCFOSell53,835$74.90$4,032,241.50View SEC Filing  
9/23/2015Elisabeth SandovalinsiderSell83,122$74.90$6,225,837.80View SEC Filing  
9/23/2015Keith KleinGeneral CounselSell52,153$74.90$3,906,259.70View SEC Filing  
9/22/2015John W. SmitherCFOSell6,645$74.91$497,776.95View SEC Filing  
9/22/2015Keith KleinGeneral CounselSell10,589$74.90$793,116.10View SEC Filing  
9/18/2015John W. SmitherCFOSell1,054$74.95$78,997.30View SEC Filing  
9/1/2015Camille D SamuelsDirectorSell250$74.72$18,680.00View SEC Filing  
6/25/2015Frederick Beddingfield IIIInsiderSell30,583$75.66$2,313,909.78View SEC Filing  
6/25/2015John W SmitherCFOSell4,600$75.50$347,300.00View SEC Filing  
5/1/2015Keith R LeonardCEOSell13,000$44.93$584,090.00View SEC Filing  
4/30/2015Elisabeth SandovalInsiderSell1,654$45.55$75,339.70View SEC Filing  
4/30/2015John W SmitherCFOSell2,041$45.49$92,845.09View SEC Filing  
4/30/2015Keith R LeonardCEOSell5,557$45.29$251,676.53View SEC Filing  
4/15/2015Keith R LeonardCEOSell2,709$50.52$136,858.68View SEC Filing  
4/1/2015Keith R LeonardCEOSell13,548$48.14$652,200.72View SEC Filing  
3/16/2015Keith R LeonardCEOSell5,312$50.16$266,449.92View SEC Filing  
3/9/2015Nathaniel E DavidDirectorSell6,185$55.00$340,175.00View SEC Filing  
3/5/2015John W SmitherCFOSell4,200$48.09$201,978.00View SEC Filing  
3/5/2015Nathaniel E DavidDirectorSell12,375$48.49$600,063.75View SEC Filing  
3/2/2015Keith R LeonardCEOSell10,625$40.94$434,987.50View SEC Filing  
3/2/2015Nathaniel E DavidDirectorSell1,875$40.78$76,462.50View SEC Filing  
2/18/2015John W SmitherCFOSell2,000$41.00$82,000.00View SEC Filing  
2/17/2015Keith R LeonardCEOSell4,165$40.46$168,515.90View SEC Filing  
2/2/2015Keith R LeonardCEOSell6,249$36.70$229,338.30View SEC Filing  
2/2/2015Nathaniel E DavidDirectorSell1,715$36.76$63,043.40View SEC Filing  
1/29/2015John W SmitherCFOSell1,000$38.00$38,000.00View SEC Filing  
1/23/2015John W SmitherCFOSell3,000$35.65$106,950.00View SEC Filing  
1/16/2015Camille D SamuelsDirectorSell250$36.70$9,175.00View SEC Filing  
1/2/2015Keith R LeonardCEOSell6,120$35.37$216,464.40View SEC Filing  
1/2/2015Nathaniel E DavidDirectorSell1,680$35.30$59,304.00View SEC Filing  
12/1/2014Keith R LeonardCEOSell5,994$37.60$225,374.40View SEC Filing  
12/1/2014Nathaniel E DavidDirectorSell1,645$37.67$61,967.15View SEC Filing  
11/3/2014Keith R LeonardCEOSell5,865$34.95$204,981.75View SEC Filing  
11/3/2014Nathaniel E DavidDirectorSell1,610$34.90$56,189.00View SEC Filing  
10/23/2014Keith R LeonardCEOSell1,913$35.13$67,203.69View SEC Filing  
10/1/2014Keith R LeonardCEOSell3,826$32.55$124,536.30View SEC Filing  
10/1/2014Nathaniel E DavidDirectorSell1,350$32.60$44,010.00View SEC Filing  
9/2/2014Nathaniel E DavidDirectorSell1,540$37.37$57,549.80View SEC Filing  
8/4/2014Keith R LeonardCEOSell1,828$35.10$64,162.80View SEC Filing  
8/4/2014Nathaniel E DavidDirectorSell1,505$33.08$49,785.40View SEC Filing  
8/1/2014Keith R LeonardCEOSell3,656$32.80$119,916.80View SEC Filing  
7/2/2014John W SmitherCFOSell2,250$40.00$90,000.00View SEC Filing  
7/2/2014Keith R LeonardCEOSell8,925$39.47$352,269.75View SEC Filing  
7/2/2014Nathaniel E DavidDirectorSell1,778$39.20$69,697.60View SEC Filing  
6/16/2014Keith R LeonardCEOSell1,743$36.58$63,758.94View SEC Filing  
6/2/2014Keith R LeonardCEOSell3,486$32.54$113,434.44View SEC Filing  
6/2/2014Nathaniel E DavidDirectorSell1,230$32.56$40,048.80View SEC Filing  
5/1/2014Keith LeonardCEOSell3,400$32.56$110,704.00View SEC Filing  
5/1/2014Nathaniel DavidDirectorSell1,200$32.60$39,120.00View SEC Filing  
4/1/2014Jeffrey WebsterVPSell4,000$39.36$157,440.00View SEC Filing  
4/1/2014Keith LeonardCEOSell13,260$39.08$518,200.80View SEC Filing  
3/20/2014John SmitherCFOSell1,125$43.78$49,252.50View SEC Filing  
3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View SEC Filing  
3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82View SEC Filing  
2/20/2014John SmitherCFOSell2,250$49.75$111,937.50View SEC Filing  
2/14/2014John SmitherCFOSell1,125$50.00$56,250.00View SEC Filing  
2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View SEC Filing  
2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.00View SEC Filing  
2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00View SEC Filing  
1/21/2014John SmitherCFOSell1,125$42.54$47,857.50View SEC Filing  
1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View SEC Filing  
1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.40View SEC Filing  
12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View SEC Filing  
12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View SEC Filing  
12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00View SEC Filing  
11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View SEC Filing  
11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View SEC Filing  
11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View SEC Filing  
9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View SEC Filing  
9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View SEC Filing  
9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View SEC Filing  
9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View SEC Filing  
9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View SEC Filing  
9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View SEC Filing  
9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00View SEC Filing  
8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View SEC Filing  
8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View SEC Filing  
8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View SEC Filing  
8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View SEC Filing  
7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View SEC Filing  
7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View SEC Filing  
7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View SEC Filing  
7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View SEC Filing  
6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View SEC Filing  
6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View SEC Filing  
6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View SEC Filing  
6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View SEC Filing  
6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View SEC Filing  
6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View SEC Filing  
5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View SEC Filing  
5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Latest Headlines for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Source:
DateHeadline
streetinsider.com logoPulmatrix (PULM) Appoints Amit Munshi to Board
www.streetinsider.com - June 16 at 7:14 AM
streetinsider.com logoPulmatrix (PULM) Appoints Amit Munshi to Board
www.streetinsider.com - June 16 at 7:14 AM
prnewswire.com logoAmit D. Munshi Joins Pulmatrix's Board of Directors
www.prnewswire.com - June 16 at 7:14 AM
prnewswire.com logoAmit D. Munshi Joins Pulmatrix's Board of Directors
www.prnewswire.com - June 16 at 7:14 AM
seekingalpha.com logoNeothetics: A Look Ahead - Seeking Alpha
seekingalpha.com - December 22 at 12:47 AM
seekingalpha.com logoNeothetics: A Look Ahead
seekingalpha.com - December 21 at 7:03 PM
globenewswire.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation with ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 6:21 PM
finance.yahoo.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation …
finance.yahoo.com - November 29 at 4:15 PM
finance.yahoo.com logoNohla Therapeutics Announces Closing of $43.5M Series A Financing to Transform Stem Cell Transplantation …
finance.yahoo.com - November 29 at 4:15 PM
investopedia.com logo6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE)
www.investopedia.com - November 19 at 8:28 AM
seekingalpha.com logoAlder BioPharmaceuticals' (ALDR) CEO Randy Schatzman on Q3 ... - Seeking Alpha
seekingalpha.com - October 28 at 9:25 AM
bloomberg.com logoAnti-Aging Startup Raises $116 Million With Bezos Backing - Bloomberg
www.bloomberg.com - October 28 at 9:25 AM
finance.yahoo.com logoUNITY Biotechnology Announces $116 Million Series B Financing
finance.yahoo.com - October 27 at 5:55 PM
businesswire.com logoBlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral Disorders - Business Wire (press release)
www.businesswire.com - October 20 at 11:34 AM
prnewswire.com logoPfenex Inc. Announces Formation of Scientific Advisory Board - PR Newswire (press release)
www.prnewswire.com - October 20 at 11:34 AM
finance.yahoo.com logoPfenex Inc. Announces Formation of Scientific Advisory Board
finance.yahoo.com - October 19 at 6:13 PM
bizjournals.com logoMedical Aesthetics Market Worth $69,786 Million by 2021
www.bizjournals.com - August 10 at 8:52 AM
streetinsider.com logoMannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - StreetInsider.com
www.streetinsider.com - August 1 at 5:45 PM
finance.yahoo.com logoMannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs
finance.yahoo.com - August 1 at 10:38 AM
businesswire.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release)
www.businesswire.com - July 13 at 6:17 PM
finance.yahoo.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Yahoo Finance
finance.yahoo.com - July 12 at 6:09 PM

Social

Chart

Kythera Biopharmaceuticals (KYTH) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff